TG Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Mar 1, 2023 and accepted by EDGAR at Mar 1, 2023, 17:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2022-01-01 to 2022-12-31 | $125.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2022-01-01 to 2022-12-31 | $70.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$192.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $10.2m | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$1.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$1.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 135,411,258 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$176.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $14.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $102.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $168.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $193.6m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $53.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $135.0m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $71.1m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-12-31 | $0 | us-gaap:LongTermDebtCurrent |
Source: SEC EDGAR, the filing index for accession 0001558370-23-002610. Last ingested by Listed: Oct 24, 2026, 15:01 ET. Listed shows no prices and gives no investment advice.